[1. Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases // Int J Hepatol, 2012; 2012:819193]Search in Google Scholar
[2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Fave GD, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours // Lancet Oncol, 2008;9:61 – 72]Search in Google Scholar
[3. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller Th, Anlauf M, Wiedenmann B, Salazar R. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary // Neuroendocrinology, 2012;95:157 – 176]Search in Google Scholar
[4. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) // Gut, 2012;61(1):6 – 32]Search in Google Scholar
[5. Strosberg J. Neuroendocrine tumours of the small intestine // Best Pract Res Clin Gastroenterol, 2012; 26:755 – 773]Search in Google Scholar
[6. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia-pathophysiology and management // J Gastroenterol, 2013; 48:574 – 594]Search in Google Scholar
[7. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States // J Clin Oncol, 2008; 26:3063 – 3072]Search in Google Scholar